Development of a high throughput drug screening assay to identify compounds that protect oligodendrocyte viability and differentiation under inflammatory conditions.

ABSTRACT:

Background

Newly proliferated oligodendrocyte precursor cells (OPCs) migrate and surround lesions of patients with multiple sclerosis (MS) and other demyelinating diseases, but fail to differentiate into oligodendrocytes (OLs) and remyelinate remaining viable axons. The abundance of secreted inflammatory factors within and surrounding these lesions likely plays a major inhibitory role, promoting cell death and preventing OL differentiation and axon remyelination. To identify clinical candidate compounds that may protect existing and differentiating OLs in patients, we have developed a high throughput screening (HTS) assay that utilizes purified rat OPCs.

Results

Using a fluorescent indicator of cell viability coupled with image quantification, we developed an assay to allow

SUBMITTER: Lariosa-Willingham KD 

PROVIDER: S-EPMC5024459 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature